PA
CHRW icon

PharVision Advisers’s C.H. Robinson CHRW Stock Holding History

PharVision Advisers’s Portfolio CHRW Stock Details CHRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,298
Closed -$235K – 293
2025
Q1 		$235K Sell
2,298
-328
-12% -$33.2K 0.33% 148
2024
Q4 		$271K Buy
+2,626
New +$283K 0.23% 188

Other funds holding CHRW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Broadwater Capital Boston, Massachusetts $134M AUM 21.11% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PharVision Advisers's CHRW Position: Q2 2025 in Review

PharVision Advisers sold out of C.H. Robinson (CHRW) in Q2 2025, closing a stake of 2,298 shares — an estimated $235K sold.

PharVision Advisers first reported a position in CHRW in Q4 2024 and held it in 2 quarters. The position peaked at $271K in Q4 2024. 665 funds tracked by Wall St. Rank hold CHRW as of Q2 2025.

  • PharVision Advisers reported no remaining C.H. Robinson position as of Q2 2025 after selling out during the quarter.
  • PharVision Advisers sold 2,298 C.H. Robinson shares in Q2 2025, an estimated $235K.
  • PharVision Advisers first reported a position in C.H. Robinson in Q4 2024 and held it in 2 quarters.
  • PharVision Advisers's C.H. Robinson position peaked at $271K in Q4 2024.
  • 665 funds tracked by Wall St. Rank held C.H. Robinson as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.